121 related articles for article (PubMed ID: 37068734)
1. Validation of the Labcorp Plasma Focus Test to Facilitate Precision Oncology Through Cell-Free DNA Genomic Profiling of Solid Tumors.
Verner EL; Jackson JB; Severson E; Valkenburg KC; Greer AE; Riley DR; Sausen M; Maddox C; McGregor PM; Karandikar A; Hastings SB; Previs RA; Reddy VP; Jensen TJ; Ramkissoon SH
J Mol Diagn; 2023 Jul; 25(7):477-489. PubMed ID: 37068734
[TBL] [Abstract][Full Text] [Related]
2. Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors.
Milbury CA; Creeden J; Yip WK; Smith DL; Pattani V; Maxwell K; Sawchyn B; Gjoerup O; Meng W; Skoletsky J; Concepcion AD; Tang Y; Bai X; Dewal N; Ma P; Bailey ST; Thornton J; Pavlick DC; Frampton GM; Lieber D; White J; Burns C; Vietz C
PLoS One; 2022; 17(3):e0264138. PubMed ID: 35294956
[TBL] [Abstract][Full Text] [Related]
3. Validation of a Circulating Tumor DNA-Based Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing.
Al Zoughbi W; Fox J; Beg S; Papp E; Hissong E; Ohara K; Keefer L; Sigouros M; Kane T; Bockelman D; Nichol D; Patchell E; Bareja R; Karandikar A; Alnajar H; Cerqueira G; Guthrie VB; Verner E; Manohar J; Greco N; Wilkes D; Tagawa S; Malbari MS; Holcomb K; Eng KW; Shah M; Altorki NK; Sboner A; Nanus D; Faltas B; Sternberg CN; Simmons J; Houvras Y; Molina AM; Angiuoli S; Elemento O; Mosquera JM
Oncologist; 2021 Nov; 26(11):e1971-e1981. PubMed ID: 34286887
[TBL] [Abstract][Full Text] [Related]
4. Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin.
Woodhouse R; Li M; Hughes J; Delfosse D; Skoletsky J; Ma P; Meng W; Dewal N; Milbury C; Clark T; Donahue A; Stover D; Kennedy M; Dacpano-Komansky J; Burns C; Vietz C; Alexander B; Hegde P; Dennis L
PLoS One; 2020; 15(9):e0237802. PubMed ID: 32976510
[TBL] [Abstract][Full Text] [Related]
5. Analytical validation and clinical utilization of K-4CARE™: a comprehensive genomic profiling assay with personalized MRD detection.
Nguyen Hoang TP; Nguyen TA; Tran NHB; Nguyen Hoang VA; Thi Dao HT; Tran VU; Nguyen YN; Nguyen AT; Nguyen Thi CT; Do Thi TT; Nguyen DS; Nguyen HN; Giang H; Tu LN
Front Mol Biosci; 2024; 11():1334808. PubMed ID: 38404964
[No Abstract] [Full Text] [Related]
6. Analytical and Clinical Validation of a Target-Enhanced Whole Genome Sequencing-Based Comprehensive Genomic Profiling Test.
Ferguson S; Sriram S; Wallace JK; Lee J; Kim JA; Lee Y; Oh BB; Lee WC; Lee S; Connolly-Strong E
Cancer Invest; 2024 May; 42(5):390-399. PubMed ID: 38773925
[TBL] [Abstract][Full Text] [Related]
7. Analytical and clinical validation of an amplicon-based next generation sequencing assay for ultrasensitive detection of circulating tumor DNA.
Poh J; Ngeow KC; Pek M; Tan KH; Lim JS; Chen H; Ong CK; Lim JQ; Lim ST; Lim CM; Goh BC; Choudhury Y
PLoS One; 2022; 17(4):e0267389. PubMed ID: 35486650
[TBL] [Abstract][Full Text] [Related]
8. Detection of Circulating Tumor DNA with a Single-Molecule Sequencing Analysis Validated for Targeted and Immunotherapy Selection.
Atkins A; Gupta P; Zhang BM; Tsai WS; Lucas J; Javey M; Vora A; Mei R
Mol Diagn Ther; 2019 Aug; 23(4):521-535. PubMed ID: 31209714
[TBL] [Abstract][Full Text] [Related]
9. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
10. Automated next-generation profiling of genomic alterations in human cancers.
Keefer LA; White JR; Wood DE; Gerding KMR; Valkenburg KC; Riley D; Gault C; Papp E; Vollmer CM; Greer A; Hernandez J; McGregor PM; Zingone A; Ryan BM; Deak K; McCall SJ; Datto MB; Prescott JL; Thompson JF; Cerqueira GC; Jones S; Simmons JK; McElhinny A; Dickey J; Angiuoli SV; Diaz LA; Velculescu VE; Sausen M
Nat Commun; 2022 May; 13(1):2830. PubMed ID: 35595835
[TBL] [Abstract][Full Text] [Related]
11. An absolute approach to using whole exome DNA and RNA workflow for cancer biomarker testing.
Malhotra R; Javle V; Tanwar N; Gowda P; Varghese L; K A; Madhusudhan N; Jaiswal N; K S B; Chatterjee M; Prabhash K; Sreekanthreddy P; Rishi KD; Goswami HM; Veldore VH
Front Oncol; 2023; 13():1002792. PubMed ID: 36994199
[TBL] [Abstract][Full Text] [Related]
12. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ
PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984
[TBL] [Abstract][Full Text] [Related]
13. Peptide-Affinity Precipitation of Extracellular Vesicles and Cell-Free DNA Improves Sequencing Performance for the Detection of Pathogenic Mutations in Lung Cancer Patient Plasma.
Taylor C; Chacko S; Davey M; Lacroix J; MacPherson A; Finn N; Wajnberg G; Ghosh A; Crapoulet N; Lewis SM; Ouellette RJ
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33260345
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.
Bustamante Alvarez JG; Janse S; Owen DH; Kiourtsis S; Bertino EM; He K; Carbone DP; Otterson GA
Clin Lung Cancer; 2021 Jul; 22(4):e519-e527. PubMed ID: 33414052
[TBL] [Abstract][Full Text] [Related]
15. Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular profiling.
Plagnol V; Woodhouse S; Howarth K; Lensing S; Smith M; Epstein M; Madi M; Smalley S; Leroy C; Hinton J; de Kievit F; Musgrave-Brown E; Herd C; Baker-Neblett K; Brennan W; Dimitrov P; Campbell N; Morris C; Rosenfeld N; Clark J; Gale D; Platt J; Calaway J; Jones G; Forshew T
PLoS One; 2018; 13(3):e0193802. PubMed ID: 29543828
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of a multigene variant profiling assay to guide targeted and immuno therapy selection in solid tumors.
Akolkar D; Patil D; Srivastava N; Patil R; Datta V; Apurwa S; Yashwante N; Dhasarathan R; Gosavi R; John J; Khan S; Jadhav N; Mene P; Ahire D; Pawar S; Bodke H; Sahoo S; Nile A; Saindane D; Darokar H; Devhare P; Srinivasan A; Datar R
PLoS One; 2021; 16(2):e0246048. PubMed ID: 33556149
[TBL] [Abstract][Full Text] [Related]
17. Accurate Pan-Cancer Molecular Diagnosis of Microsatellite Instability by Single-Molecule Molecular Inversion Probe Capture and High-Throughput Sequencing.
Waalkes A; Smith N; Penewit K; Hempelmann J; Konnick EQ; Hause RJ; Pritchard CC; Salipante SJ
Clin Chem; 2018 Jun; 64(6):950-958. PubMed ID: 29632127
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Validation of a Comprehensive Targeted Panel for Broad Mutational and Biomarker Analysis in Solid Tumors.
Froyen G; Geerdens E; Berden S; Cruys B; Maes B
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626061
[TBL] [Abstract][Full Text] [Related]
19. Targeted RNA sequencing for upfront analysis of actionable driver alterations in non-small cell lung cancer.
Claerhout S; Lehnert S; Vander Borght S; Spans L; Dooms C; Wauters E; Vansteenkiste J; Weynand B; Deraedt K; Bourgain C; Vanden Bempt I
Lung Cancer; 2022 Apr; 166():242-249. PubMed ID: 35378489
[TBL] [Abstract][Full Text] [Related]
20. European Real-World Assessment of the Clinical Validity of a CE-IVD Panel for Ultra-Fast Next-Generation Sequencing in Solid Tumors.
Normanno N; Machado JC; Pescarmona E; Buglioni S; Navarro L; Esposito Abate R; Ferro A; Mensink R; Lambiase M; Lespinet-Fabre V; Calgua B; Jermann PM; Ilié M; Hofman P
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]